Andrew J Aschenbrenner1, Brian A Gordon1, Tammie L S Benzinger1, John C Morris1, Jason J Hassenstab2. 1. From the Charles F. and Joanne Knight Alzheimer Disease Research Center (A.J.A., B.A.G., T.L.S.B., J.C.M., J.J.H.), Department of Neurology (J.C.M., J.J.H.), Department of Psychological & Brain Sciences (B.A.G., J.J.H.), and Department of Radiology (B.A.G., T.L.S.B.), Washington University in St. Louis, MO. 2. From the Charles F. and Joanne Knight Alzheimer Disease Research Center (A.J.A., B.A.G., T.L.S.B., J.C.M., J.J.H.), Department of Neurology (J.C.M., J.J.H.), Department of Psychological & Brain Sciences (B.A.G., J.J.H.), and Department of Radiology (B.A.G., T.L.S.B.), Washington University in St. Louis, MO. hassenstabj@wustl.edu.
Abstract
OBJECTIVE: To examine the independent and interactive influences of neuroimaging biomarkers on retrospective cognitive decline. METHODS: A total of 152 middle-aged and older adult participants with at least 2 clinical and cognitive assessments, a Clinical Dementia Rating score of 0 or 0.5, and a flortaucipir (18F-AV-1451) tau PET scan, a florbetapir (18F-AV-45) amyloid PET scan, and a structural MRI scan were recruited from the Knight Alzheimer Disease Research Center at Washington University in St. Louis. Cognition was assessed with standard measures reflecting episodic memory, executive functioning, semantic fluency, and processing speed. RESULTS: Results from retrospective longitudinal analyses showed that each biomarker had a univariate association with the global cognitive composite; however, when each marker was analyzed in a single statistical model, only tau was a significant predictor of global cognitive decline. There was an interaction between tau and amyloid such that tau-related cognitive decline was worse in individuals with high amyloid. There was also an interaction with hippocampal volume indicating that individuals with high levels of all 3 pathologies exhibited the greatest declines in cognition. Additional analyses within each cognitive domain indicated that tau had the largest negative influence on tests of episodic memory and executive functioning. CONCLUSIONS: Together, these results suggest that increasing levels of tau most consistently relate to declines in cognition preceding biomarker collection. These findings support models of Alzheimer disease (AD) staging that suggest that elevated β-amyloid alone may be insufficient to produce cognitive change in individuals at risk for AD and support the use of multiple biomarkers to stage AD progression.
OBJECTIVE: To examine the independent and interactive influences of neuroimaging biomarkers on retrospective cognitive decline. METHODS: A total of 152 middle-aged and older adult participants with at least 2 clinical and cognitive assessments, a Clinical Dementia Rating score of 0 or 0.5, and a flortaucipir (18F-AV-1451) tau PET scan, a florbetapir (18F-AV-45) amyloid PET scan, and a structural MRI scan were recruited from the Knight Alzheimer Disease Research Center at Washington University in St. Louis. Cognition was assessed with standard measures reflecting episodic memory, executive functioning, semantic fluency, and processing speed. RESULTS: Results from retrospective longitudinal analyses showed that each biomarker had a univariate association with the global cognitive composite; however, when each marker was analyzed in a single statistical model, only tau was a significant predictor of global cognitive decline. There was an interaction between tau and amyloid such that tau-related cognitive decline was worse in individuals with high amyloid. There was also an interaction with hippocampal volume indicating that individuals with high levels of all 3 pathologies exhibited the greatest declines in cognition. Additional analyses within each cognitive domain indicated that tau had the largest negative influence on tests of episodic memory and executive functioning. CONCLUSIONS: Together, these results suggest that increasing levels of tau most consistently relate to declines in cognition preceding biomarker collection. These findings support models of Alzheimer disease (AD) staging that suggest that elevated β-amyloid alone may be insufficient to produce cognitive change in individuals at risk for AD and support the use of multiple biomarkers to stage AD progression.
Authors: Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris Journal: Neurobiol Aging Date: 2009-04-18 Impact factor: 4.673
Authors: Liang Wang; Tammie L Benzinger; Jason Hassenstab; Tyler Blazey; Christopher Owen; Jingxia Liu; Anne M Fagan; John C Morris; Beau M Ances Journal: Neurology Date: 2015-02-25 Impact factor: 9.910
Authors: Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger Journal: Neuroimage Date: 2014-12-05 Impact factor: 6.556
Authors: Yawu Liu; Valtteri Julkunen; Teemu Paajanen; Eric Westman; Lars-Olof Wahlund; Andrew Aitken; Tomasz Sobow; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Sebastian Muehlboeck; Christian Spenger; Simon Lovestone; Andrew Simmons; Hilkka Soininen Journal: Neuroradiology Date: 2012-01-14 Impact factor: 2.804
Authors: Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances Journal: Sci Transl Med Date: 2016-05-11 Impact factor: 17.956
Authors: Yi Su; Gina M D'Angelo; Andrei G Vlassenko; Gongfu Zhou; Abraham Z Snyder; Daniel S Marcus; Tyler M Blazey; Jon J Christensen; Shivangi Vora; John C Morris; Mark A Mintun; Tammie L S Benzinger Journal: PLoS One Date: 2013-11-06 Impact factor: 3.240
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Howard H Feldman; Giovanni B Frisoni; Harald Hampel; William J Jagust; Keith A Johnson; David S Knopman; Ronald C Petersen; Philip Scheltens; Reisa A Sperling; Bruno Dubois Journal: Neurology Date: 2016-07-01 Impact factor: 9.910
Authors: Peter R Millar; Beau M Ances; Brian A Gordon; Tammie L S Benzinger; John C Morris; David A Balota Journal: J Cogn Neurosci Date: 2020-11-02 Impact factor: 3.225
Authors: Stephanie A Schultz; Brian A Gordon; Shruti Mishra; Yi Su; John C Morris; Beau M Ances; Janet M Duchek; David A Balota; Tammie L S Benzinger Journal: Brain Imaging Behav Date: 2020-12 Impact factor: 3.978
Authors: Brian A Gordon; Tyler M Blazey; Jon Christensen; Aylin Dincer; Shaney Flores; Sarah Keefe; Charles Chen; Yi Su; Eric M McDade; Guoqiao Wang; Yan Li; Jason Hassenstab; Andrew Aschenbrenner; Russ Hornbeck; Clifford R Jack; Beau M Ances; Sarah B Berman; Jared R Brosch; Douglas Galasko; Serge Gauthier; James J Lah; Mario Masellis; Christopher H van Dyck; Mark A Mintun; Gregory Klein; Smiljana Ristic; Nigel J Cairns; Daniel S Marcus; Chengjie Xiong; David M Holtzman; Marcus E Raichle; John C Morris; Randall J Bateman; Tammie L S Benzinger Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust Journal: J Neurosci Date: 2020-11-20 Impact factor: 6.167
Authors: Andrew J Aschenbrenner; Brian A Gordon; Anne M Fagan; Suzanne E Schindler; David A Balota; John C Morris; Jason J Hassenstab Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Stephanie A Schultz; Brian A Gordon; Shruti Mishra; Yi Su; Richard J Perrin; Nigel J Cairns; John C Morris; Beau M Ances; Tammie L S Benzinger Journal: Neurobiol Aging Date: 2018-09-01 Impact factor: 4.673